Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Raised to $38.00 at Piper Sandler
Supernus Pharmaceuticals (NASDAQ:SUPN) Price Target Raised to $38.00 at Piper Sandler
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) had its price objective boosted by Piper Sandler from $33.00 to $38.00 in a research note issued to investors on Wednesday morning, The Fly reports. They currently have an overweight rating on the specialty pharmaceutical company's stock.
據The Fly報道,派珀·桑德勒週三上午向投資者發佈的一份研究報告將Supernus PharmPharmticals(納斯達克:SUPN-GET評級)的目標價從33美元上調至38美元。他們目前對這家專業製藥公司的股票給予了增持評級。
Supernus Pharmaceuticals Trading Up 2.2 %
Supernus製藥公司股價上漲2.2%
Shares of SUPN opened at $34.23 on Wednesday. The stock's 50 day moving average is $31.35 and its two-hundred day moving average is $30.22. The firm has a market capitalization of $1.83 billion, a PE ratio of 33.89 and a beta of 1.04. Supernus Pharmaceuticals has a twelve month low of $24.95 and a twelve month high of $36.08.
週三,SUPN的股價開盤報34.23美元。該股的50日移動均線切入位為31.35美元,200日移動均線切入位為30.22美元。該公司的市值為18.3億美元,市盈率為33.89倍,貝塔係數為1.04。Supernus PharmPharmticals的12個月低點為24.95美元,12個月高位為36.08美元。
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last issued its quarterly earnings results on Thursday, August 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.29 by ($0.15). The business had revenue of $170.10 million during the quarter, compared to analyst estimates of $164.23 million. Supernus Pharmaceuticals had a net margin of 9.12% and a return on equity of 6.98%. The company's revenue was up 20.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.43 earnings per share. On average, sell-side analysts predict that Supernus Pharmaceuticals will post 1.51 EPS for the current year.
超威製藥(納斯達克代碼:SUPN-GET評級)最近一次發佈季度收益報告是在8月4日(星期四)。這家專業製藥公司公佈本季度每股收益為0.14美元,低於普遍預期的0.29美元(0.15美元)。該業務本季度營收為1.701億美元,而分析師預期為1.6423億美元。Supernus製藥公司的淨利潤率為9.12%,股本回報率為6.98%。該公司的收入同比增長了20.4%。去年同一季度,該公司公佈的每股收益為0.43美元。賣方分析師平均預測,Supernus PharmPharmticals本年度每股收益將達到1.51股。
Insider Buying and Selling at Supernus Pharmaceuticals
Supernus製藥公司的內幕買賣
Hedge Funds Weigh In On Supernus Pharmaceuticals
對衝基金參與Supernus PharmPharmticals
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SUPN. ProShare Advisors LLC boosted its stake in shares of Supernus Pharmaceuticals by 4.4% during the 4th quarter. ProShare Advisors LLC now owns 19,862 shares of the specialty pharmaceutical company's stock valued at $578,000 after buying an additional 843 shares during the period. State Board of Administration of Florida Retirement System raised its holdings in Supernus Pharmaceuticals by 4.3% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 97,789 shares of the specialty pharmaceutical company's stock worth $2,852,000 after acquiring an additional 3,997 shares during the period. Bank of America Corp DE raised its holdings in Supernus Pharmaceuticals by 10.9% in the 4th quarter. Bank of America Corp DE now owns 534,919 shares of the specialty pharmaceutical company's stock worth $15,597,000 after acquiring an additional 52,661 shares during the period. Natixis Advisors L.P. raised its holdings in Supernus Pharmaceuticals by 22.5% in the 4th quarter. Natixis Advisors L.P. now owns 26,997 shares of the specialty pharmaceutical company's stock worth $787,000 after acquiring an additional 4,953 shares during the period. Finally, First Republic Investment Management Inc. grew its position in Supernus Pharmaceuticals by 5.9% in the 4th quarter. First Republic Investment Management Inc. now owns 22,595 shares of the specialty pharmaceutical company's stock worth $659,000 after purchasing an additional 1,262 shares during the last quarter. Institutional investors and hedge funds own 99.81% of the company's stock.
一些對衝基金和其他機構投資者最近增持或減持了SUPN的股份。ProShare Advisors LLC在第四季度將其在Supernus PharmPharmticals的股份增加了4.4%。ProShare Advisors LLC現在擁有這家專業製藥公司的19862股,價值578,000美元,在此期間又購買了843股。佛羅裏達州行政管理委員會退休系統在第四季度將其在Supernus PharmPharmticals的持股增加了4.3%。佛羅裏達州行政管理委員會退休系統現在擁有97,789股這家專業製藥公司的股票,價值2,852,000美元,在此期間額外購買了3,997股。美國銀行DE在第四季度增持Supernus PharmPharmticals的股份10.9%。美國銀行DE現在擁有534,919股這家專業製藥公司的股票,價值15,597,000美元,在此期間又購買了52,661股。Natixis Advisors L.P.在第四季度將其在Supernus PharmPharmticals的持股增加了22.5%。Natixis Advisors L.P.在此期間額外收購了4953股,現在擁有26,997股這家專業製藥公司的股票,價值78.7萬美元。最後,First Republic Investment Management Inc.在第四季度將其在Supernus製藥公司的頭寸增加了5.9%。First Republic Investment Management Inc.現在持有這家專業製藥公司22,595股股票,價值65.9萬美元,該公司在上個季度又購買了1,262股股票。機構投資者和對衝基金持有該公司99.81%的股票。
Supernus Pharmaceuticals Company Profile
Supernus製藥公司簡介
(Get Rating)
(獲取評級)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
Supernus製藥公司是一家生物製藥公司,在美國專注於治療中樞神經系統(CNS)疾病的產品的開發和商業化。它的商業產品是Trokendi XR,這是一種用於治療癲癇和預防偏頭痛的託吡酯緩釋劑;奧克泰拉XR是一種緩釋型奧卡西平,用於單一療法治療6至17歲的成人和兒童部分發作癲癇。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- Can Alibaba And Baidu Finally Rally With Delisting Fears Gone?
- 3 Materials Stocks That May Earn a Place on Your Watchlist
- Is World Wresting Entertainment Getting Ready to Be Sold?
- Crowdstrike Stock Retraces, As Earnings Sober Expectations
- Will The Institutions Buy The Dip In Ambarella Stock?
- 免費獲取StockNews.com關於Supernus製藥公司的研究報告(SUPN)
- 阿里巴巴-SW和百度集團-SW最終能在退市恐懼中重整旗鼓嗎?
- 3種可能在你的觀察名單上獲得一席之地的材料類股
- 世界摔跤娛樂公司準備被出售了嗎?
- CrowdStrike股價回落,盈利超出預期
- 這些機構會在安巴雷拉入股抄底嗎?
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
獲得Supernus PharmPharmticals Daily的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Supernus製藥公司和相關公司的最新新聞和分析師評級的每日摘要。